Affordable Access

deepdyve-link
Publisher Website

Targeted Downregulation of kdm4a Ameliorates Tau-engendered Defects in Drosophila melanogaster.

Authors
  • Park, Sung Yeon1, 2
  • Seo, Jieun2, 3
  • Chun, Yang Sook1, 2, 4
  • 1 Ischemic/Hypoxic Disease Institute, Seoul National University College of Medicine, Seoul, Korea. , (North Korea)
  • 2 Department of Physiology, Seoul National University College of Medicine, Seoul, Korea. , (North Korea)
  • 3 Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Korea. , (North Korea)
  • 4 Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Korea. [email protected] , (North Korea)
Type
Published Article
Journal
Journal of Korean medical science
Publication Date
Aug 26, 2019
Volume
34
Issue
33
Identifiers
DOI: 10.3346/jkms.2019.34.e225
PMID: 31436053
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Tauopathies, a class of neurodegenerative diseases that includes Alzheimer's disease (AD), are characterized by the deposition of neurofibrillary tangles composed of hyperphosphorylated tau protein in the human brain. As abnormal alterations in histone acetylation and methylation show a cause and effect relationship with AD, we investigated the role of several Jumonji domain-containing histone demethylase (JHDM) genes, which have yet to be studied in AD pathology. To examine alterations of several JHDM genes in AD pathology, we performed bioinformatics analyses of JHDM gene expression profiles in brain tissue samples from deceased AD patients. Furthermore, to investigate the possible relationship between alterations in JHDM gene expression profiles and AD pathology in vivo, we examined whether tissue-specific downregulation of JHDM Drosophila homologs (kdm) can affect tauR406W-induced neurotoxicity using transgenic flies containing the UAS-Gal4 binary system. The expression levels of JHDM1A, JHDM2A/2B, and JHDM3A/3B were significantly higher in postmortem brain tissue from patients with AD than from non-demented controls, whereas JHDM1B mRNA levels were downregulated in the brains of patients with AD. Using transgenic flies, we revealed that knockdown of kdm2 (homolog to human JHDM1), kdm3 (homolog to human JHDM2), kdm4a (homolog to human JHDM3A), or kdm4b (homolog to human JHDM3B) genes in the eye ameliorated the tauR406W-engendered defects, resulting in less severe phenotypes. However, kdm4a knockdown in the central nervous system uniquely ameliorated tauR406W-induced locomotion defects by restoring heterochromatin. Our results suggest that downregulation of kdm4a expression may be a potential therapeutic target in AD. © 2019 The Korean Academy of Medical Sciences.

Report this publication

Statistics

Seen <100 times